QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.059097v1 308/2/555    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Draheim, R. Articles by Rundfeldt, C. Search for Related Content PubMed PubMed Citation Articles by Draheim, R. Articles by Rundfeldt, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

INFLAMMATION AND IMMUNOPHARMACOLOGY

Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 Inhibitor N-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations

Departments of Pharmacology and Molecular Biology, elbion AG, Radebeul, Germany

AWD 12-281 is a potent (IC₅₀ = 9.7 nM) and highly selective inhibitor of the phosphodiesterase 4 (PDE4) isoenzyme with low affinity to the high-affinity rolipram-binding site. The compound was optimized for topical treatment of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The aim of the present study was to assess the effect of AWD 12-281 in human inflammatory cells. Peripheral blood mononuclear cells (PBMCs), diluted whole blood, and human nasal polyp cells derived from surgically resected nasal polyps from patients with polyposis comprise sources of target tissue cells that can be used to predict anti-inflammatory effects in patients. AWD 12-281 was capable of suppressing the production of cytokines in stimulated PBMCs: interleukin-2 (IL-2, phytohemagglutinin stimulation), IL-5 (concanavalin A stimulation), IL-5 and IL-4 (anti-CD3/anti-CD28 costimulation), and lipopolysaccharide-stimulated release of tumor necrosis factor (TNF). The corresponding values for half-maximum inhibition, EC₅₀, for AWD 12-281 were within a narrow range (46–121 nM). Comparing the effect of AWD 12-281 with roflumilast, cilomilast (SB 207499), rolipram (RPR-73401), and 1-(3-nitrophenyl)-3-(4-pyridylmethyl)pyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (RS-25344-000), it could be shown that the PDE4 inhibitory activity was closely correlated with inhibitory potential as measured by the above-described assays. AWD 12-281 was also shown to suppress TNF release in dispersed nasal polyps (EC₅₀ = 111 nM) and in diluted whole blood (EC₅₀ = 934 nM). The reduced activity in human blood may be related to high plasma protein binding. Currently, phase II clinical studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis.

Address correspondence to: Regina Draheim, Department of Pharmacology, elbion AG, Meissner Str. 191, D-01445 Radebeul, Germany. E-mail: regina.draheim{at}elbion.de

This article has been cited by other articles:

				S. B Karish and J. M Gagnon The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor Ann. Pharmacother., June 1, 2006; 40(6): 1096 - 1104. [Abstract] [Full Text] [PDF]